Neurologia最新文献

{"title":"Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice","authors":"P. Pérez-Torre ,&nbsp;J.L. López-Sendón ,&nbsp;V. Mañanes Barral ,&nbsp;I. Parees ,&nbsp;S. Fanjul-Arbós ,&nbsp;E. Monreal ,&nbsp;A. Alonso-Canovas ,&nbsp;J.C. Martínez Castrillo","doi":"10.1016/j.nrleng.2021.08.005","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.08.005","url":null,"abstract":"<div><h3>Background and purpose</h3><p>The aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life.</p></div><div><h3>Methods</h3><p>We conducted a retrospective observational study of patients with Parkinson's disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for. Also, we collected time of simultaneous use, doses of levodopa and other antiparkinsonian drugs.</p></div><div><h3>Results</h3><p>Clinical records were reviewed for the study period of September 2018 to September 2019. Seventy-eight PD patients who were treated with safinamide of which 25 (32.05%) had a concomitant treatment with an antidepressant drug, being sertraline and escitalopram the most frequent. Mean age was 80 years<!--> <!-->±<!--> <!-->8.43 and H&amp;Y stage was 3 [2–4]. Mean dose of levodopa used was 703.75<!--> <!-->mg<!--> <!-->±<!--> <!-->233.15. Median duration of concomitant treatment with safinamide and antidepressant drug was 6 months (IQR 20.5), and over eighteen months in 5 cases. No case of serotonin syndrome was recorded, neither was any of its typical manifestations combined or in isolation.</p></div><div><h3>Conclusions</h3><p>Our real clinical practice study suggests that concomitant use of safinamide with antidepressant drugs in PD patients seemed to be safe and well tolerated, even in the long term. However, caution is warranted, individualizing treatment regimens and monitoring the potential appearance of adverse effects.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 4","pages":"Pages 340-344"},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000361/pdfft?md5=2257d8b81f4fd87afd9a8edc2202ed0c&pid=1-s2.0-S2173580824000361-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors affecting resolution of oculomotor nerve palsy following endovascular embolization of posterior communicating artery aneurysms","authors":"C.G. Chen ,&nbsp;J.W. Wang ,&nbsp;J.F. Li ,&nbsp;C.H. Li ,&nbsp;B.L. Gao","doi":"10.1016/j.nrleng.2021.07.006","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.07.006","url":null,"abstract":"<div><h3>Purpose</h3><p>To investigate the effect of endovascular embolization of posterior communicating artery (Pcom) aneurysms on concomitant oculomotor nerve palsy (OMNP) and factors affecting the effect of treatment.</p></div><div><h3>Materials and methods</h3><p>Patients with the Pcom aneurysms concomitant with OMNP were retrospectively enrolled for endovascular treatment of the aneurysms. All patients had the endovascular management. The clinical effect, degree of OMNP, size of the aneurysm, type of treatment, subarachnoid hemorrhage (SAH), and time from onset to treatment were analyzed on the resolution of OMNP.</p></div><div><h3>Results</h3><p>Ninety-six patients with 99 Pcom aneurysms were enrolled and treated endovascularly, with the success rate of 100%. Immediately after endovascular treatment, 75 aneurysms (75.75%) got complete occlusion, and 24 (24.24%) nearly complete occlusion. Followed up for 3–18 (mean 8.52<!--> <!-->±<!--> <!-->0.56) months, complete resolution of the OMNP was achieved in 63 patients (65.63%), partial resolution in 21 (21.88%), and non-recovery in the other 12 (12.50%). The degree of OMNP at onset, SAH, and time from onset to treatment were significantly (<em>P</em> <!-->&lt;<!--> <!-->0.05) correlated with the resolution of OMNP. Univariate analysis revealed that younger age of the patient, degree of OMNP at onset, presence of subarachnoid hemorrhage, and time from disease onset to treatment were significantly (<em>P</em> <!-->&lt;<!--> <!-->0.05) associated with the recovery of OMNP. Multivariate analysis revealed that the younger age, degree of OMNP at onset, and time from disease onset to treatment were significantly (<em>P</em> <!-->&lt;<!--> <!-->0.05) associated with the recovery of OMNP.</p></div><div><h3>Conclusion</h3><p>Endovascular embolization of Pcom aneurysms concomitant with OMNP can effectively improve the OMNP symptoms, especially for patients with moderate and a shorter history of OMNP. Younger age, degree of oculomotor nerve palsy at onset, and time from onset to treatment may significantly affect recovery of oculomotor nerve palsy.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 4","pages":"Pages 315-320"},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000336/pdfft?md5=95f4e949df4fe0ec9dc625df047b1dd5&pid=1-s2.0-S2173580824000336-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of long non-coding RNA HAS2-AS1 as a diagnostic and prognostic marker of glioma","authors":"A. You ,&nbsp;J. Gu ,&nbsp;J. Wang ,&nbsp;J. Li ,&nbsp;Y. Zhang ,&nbsp;G. Rao ,&nbsp;X. Ge ,&nbsp;K. Zhang ,&nbsp;X. Gao ,&nbsp;D. Wang","doi":"10.1016/j.nrleng.2021.06.008","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.06.008","url":null,"abstract":"<div><h3>Background</h3><p>Glioma presents high incidence and poor prognosis, and therefore more effective treatments are needed. Studies have confirmed that long non-coding RNAs (lncRNAs) basically regulate various human diseases including glioma. It has been theorized that HAS2-AS1 serves as an lncRNA to exert an oncogenic role in varying cancers. This study aimed to assess the value of lncRNA HAS2-AS1 as a diagnostic and prognostic marker for glioma.</p></div><div><h3>Methods</h3><p>The miRNA expression data and clinical data of glioma were downloaded from the TCGA database for differential analysis and survival analysis. In addition, pathological specimens and specimens of adjacent normal tissue from 80 patients with glioma were used to observe the expression of HAS2-AS1. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic ability and prognostic value of HAS2-AS1 in glioma. Meanwhile, a Kaplan–Meier survival curve was plotted to evaluate the survival of glioma patients with different HAS2-AS1 expression levels.</p></div><div><h3>Results</h3><p>HAS2-AS1 was significantly upregulated in glioma tissues compared with normal tissue. The survival curves showed that overexpression of HAS2-AS1 was associated with poor overall survival (OS) and progression-free survival (PFS). Several clinicopathological factors of glioma patients, including tumor size and WHO grade, were significantly correlated with HAS2-AS1 expression in tissues. The ROC curve showed an area under the curve (AUC) value of 0.863, indicating that HAS2-AS1 had good diagnostic value. The ROC curve for the predicted OS showed an AUC of 0.906, while the ROC curve for predicted PFS showed an AUC of 0.88. Both suggested that overexpression of HAS2-AS1 was associated with poor prognosis.</p></div><div><h3>Conclusions</h3><p>Normal tissues could be clearly distinguished from glioma tissues based on HAS2-AS1 expression. Moreover, overexpression of HAS2-AS1 indicated poor prognosis in glioma patients. Therefore, HAS2-AS1 could be used as a diagnostic and prognostic marker for glioma.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 4","pages":"Pages 353-360"},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000580/pdfft?md5=ea765987229063810b4a91cda81888ae&pid=1-s2.0-S2173580824000580-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic predisposition of BDNF (rs6265) gene is susceptible to Schizophrenia: A prospective study and updated meta-analysis","authors":"M. Vajagathali,&nbsp;V. Ramakrishnan","doi":"10.1016/j.nrleng.2024.03.001","DOIUrl":"https://doi.org/10.1016/j.nrleng.2024.03.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Genetic polymorphism in the <em>BDNF</em> gene has been found to cause neuronal alterations and has been identified as a causal factor for many neuropsychiatric disorders. Therefore, various neurological case–control studies and meta-analyses have been conducted to find the possible link between <em>BDNF</em> and susceptibility to schizophrenia.</p></div><div><h3>Method</h3><p>This meta-analysis gathered data from 25 case–control studies including a total of 8384 patients with schizophrenia and 8821 controls in order to identify the relationship between the rs6265 single nucleotide polymorphism and the disease, evaluating the combined odds ratio and 95% confidence intervals under 5 different genetic models. Validation followed the “Leave one out” method, and we used the Egger test and Begg's funnel plot to identify publication bias.</p></div><div><h3>Results</h3><p>Research into the rs6265 (G/A) polymorphism revealed a non-significant association with schizophrenia in all 5 genetic models; in the subgroup analysis, no association was found between white and Asian populations, with a <em>p</em> value<!--> <!-->&gt;<!--> <!-->.05.</p></div><div><h3>Conclusions</h3><p>Overall, the updated meta-analysis revealed that rs6265 exonic polymorphisms do not increase susceptibility to this disease. However, to better understand the pathogenesis of the disease, there is a need for further case–control studies into the <em>BDNF</em> polymorphism including larger sample sizes and different ethnic groups.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 4","pages":"Pages 361-371"},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S217358082400049X/pdfft?md5=2cf6c1ac13b0b0707d2c11dee02f25ea&pid=1-s2.0-S217358082400049X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between inflammation and oxidative stress and its effect on multiple sclerosis","authors":"E.J. Ramos-González ,&nbsp;O.K. Bitzer-Quintero ,&nbsp;G. Ortiz ,&nbsp;J.J. Hernández-Cruz ,&nbsp;L.J. Ramírez-Jirano","doi":"10.1016/j.nrleng.2021.10.010","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.10.010","url":null,"abstract":"<div><h3>Introduction</h3><p>This paper highlights the relationship of inflammation and oxidative stress as damage mechanisms of Multiple Sclerosis (MS), considered an inflammatory and autoimmune disease.</p></div><div><h3>Development</h3><p>The oxidative stress concept has been defined by an imbalance between oxidants and antioxidants in favor of the oxidants. There is necessary to do physiological functions, like the respiration chain, but in certain conditions, the production of reactive species overpassed the antioxidant systems, which could cause tissue damage. On the other hand, it is well established that inflammation is a complex reaction in the vascularized connective tissue in response to diverse stimuli. However, an unregulated prolonged inflammatory process also can induce tissue damage.</p></div><div><h3>Conclusion</h3><p>Both inflammation and oxidative stress are interrelated since one could promote the other, leading to a toxic feedback system, which contributes to the inflammatory and demyelination process in MS.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 3","pages":"Pages 292-301"},"PeriodicalIF":0.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000324/pdfft?md5=81676caa9915196572f9fb21c478d335&pid=1-s2.0-S2173580824000324-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140309834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Covid-19 in Parkinson's Disease treated by drugs or brain stimulation","authors":"M. Salari ,&nbsp;M. Etemadifar ,&nbsp;A. Zali ,&nbsp;Z. Aminzade ,&nbsp;I. Navalpotro-Gomez ,&nbsp;S. Tehrani Fateh","doi":"10.1016/j.nrleng.2021.07.005","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.07.005","url":null,"abstract":"<div><h3>Purpose</h3><p>Covid-19 has affected all people, especially those with chronic diseases, including Parkinson's Disease (PD). Covid-19 may affect both motor and neuropsychiatric symptoms of PD patients. We intend to evaluate different aspects of Covid-19 impact on PD patients.</p></div><div><h3>Methods</h3><p>647 PD patients were evaluated in terms of PD-related and Covid-19-related clinical presentations in addition to past medical history during the pandemic through an online questioner. They were compared with an age-matched control group consist of 673 individuals and a sample of the normal population consist of 1215 individuals.</p></div><div><h3>Results</h3><p>The prevalence of Covid-19 in PD patients was 11.28%. The mortality was 1.23% among PD patients. The prevalence of Covid-19 in PD patients who undergone Deep Brain Stimulation (DBS) was 18.18%. No significant association was found between the duration of disease and the prevalence of Covid-19. A statistically significant higher prevalence of Covid-19 in PD patients who had direct contact with SARS-CoV-19 infected individuals was found. No statistically significant association has been found between the worsening of motor symptoms and Covid-19. PD patients and the normal population may differ in the prevalence of some psychological disorders, including anxiety and sleeping disorders, and Covid-19 may affect the psychological status.</p></div><div><h3>Conclusion</h3><p>PD patients possibly follow tighter preventive protocols, which lead to lower prevalence and severity of Covid-19 and its consequences in these patients. Although it seems Covid-19 does not affect motor and psychological aspects of PD as much as it was expected, more accurate evaluations are suggested in order to clarify such effects.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 3","pages":"Pages 254-260"},"PeriodicalIF":0.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000312/pdfft?md5=c8e32d112013c9e2bd4fef37dd944880&pid=1-s2.0-S2173580824000312-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140309882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive rehabilitation program in patients with multiple sclerosis: A pilot study","authors":"R.M. Jiménez-Morales ,&nbsp;Y. Broche-Pérez ,&nbsp;Y. Macías-Delgado ,&nbsp;C. Sebrango ,&nbsp;S. Díaz-Díaz ,&nbsp;R. Castiñeira-Rodriguez ,&nbsp;F.J. Pérez-González ,&nbsp;C. Forn","doi":"10.1016/j.nrleng.2024.01.001","DOIUrl":"https://doi.org/10.1016/j.nrleng.2024.01.001","url":null,"abstract":"<div><h3>Introduction</h3><p>In recent years, there has been an increase of studies dedicated to cognitive rehabilitation in patients with multiple sclerosis (MS); however, few of these analyze the impact on such variables as cognitive reserve. The study aims to explore the effects of a cognitive rehabilitation program comprising a combination of cognitive and physical exercises, as well as group sessions to improve cognitive performance, emotional state, and cognitive reserve index.</p></div><div><h3>Method</h3><p>Fifty patients with MS were subdivided into 2 groups: the control group, which performed aerobic exercise (<em>n</em> <!-->=<!--> <!-->25), and the experimental group (<em>n</em> <!-->=<!--> <!-->25), which participated in the integrated cognitive rehabilitation program (ICRP). All participants were evaluated 3 times (baseline, post-treatment, and long-term) with the Brief Repeatable Battery of Neuropsychological Tests, Cognitive Reserve Scale, Beck Depression Inventory, and a scale evaluating trait and state anxiety.</p></div><div><h3>Results</h3><p>Compared with the control group, patients in the experimental group showed improvements in cognitive function, with significant changes in measures of information processing speed, attention, memory, cognitive reserve index, and long-term mood.</p></div><div><h3>Conclusions</h3><p>The ICRP was effective in improving cognitive and emotional function in MS, and increased the cognitive reserve index.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 2","pages":"Pages 135-146"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000026/pdfft?md5=63c914bc4bdcf3fc1e2f5a59921e7b76&pid=1-s2.0-S2173580824000026-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuropsychological performance and disease burden in individuals at risk of developing Huntington disease","authors":"F. Paz-Rodríguez ,&nbsp;M. Chávez-Oliveros ,&nbsp;A. Bernal-Pérez ,&nbsp;A. Ochoa-Morales ,&nbsp;L. Martínez-Ruano ,&nbsp;A. Camacho-Molina ,&nbsp;Y. Rodríguez-Agudelo","doi":"10.1016/j.nrleng.2024.01.006","DOIUrl":"10.1016/j.nrleng.2024.01.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Huntington disease (HD) is a hereditary neurodegenerative disorder. Thanks to predictive diagnosis, incipient clinical characteristics have been described in the prodromal phase.</p></div><div><h3>Objective</h3><p>To compare performance in cognitive tasks of carriers (HDC) and non-carriers (non-HDC) of the huntingtin gene and to analyse the variability in performance as a function of disease burden and proximity to the manifest stage (age of symptom onset).</p></div><div><h3>Method</h3><p>A sample of 146 participants in a predictive diagnosis of HD programme were divided into the HDC (41.1%) and non-HDC groups (58.9%). Mathematical formulae were used to calculate disease burden and proximity to the manifest stage in the HDC group; these parameters were correlated with neuropsychological performance.</p></div><div><h3>Results</h3><p>Significant differences were observed between groups in performance on the Mini–Mental State Examination (MMSE), Stroop-B, Symbol-Digit Modalities Test (SDMT), and phonological fluency. In the HDC group, correlations were observed between disease burden and performance on the MMSE, Stroop-B, and SDMT. The group of patients close to the manifest stage scored lowest on the MMSE, Stroop-B, Stroop-C, SDMT, and semantic verbal fluency. According to the multivariate analysis of covariance, the MMSE effect shows statistically significant differences in disease burden and proximity to onset of symptoms.</p></div><div><h3>Conclusions</h3><p>Members of the HDC group close to the manifest phase performed more poorly on tests assessing information processing speed and attention. Prefrontal cognitive dysfunction appears early, several years before the motor diagnosis of HD.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 2","pages":"Pages 127-134"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000221/pdfft?md5=dbd1293899d67f78ab166d37589a4bf4&pid=1-s2.0-S2173580824000221-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual snow syndrome and its relationship with migraine","authors":"O. Barrachina-Esteve ,&nbsp;I. Hidalgo-Torrico ,&nbsp;C. Acero ,&nbsp;S. Aranceta ,&nbsp;D. Cánovas-Vergé ,&nbsp;G. Ribera","doi":"10.1016/j.nrleng.2021.05.012","DOIUrl":"10.1016/j.nrleng.2021.05.012","url":null,"abstract":"<div><h3>Introduction</h3><p>Visual snow syndrome (VSS) is a central nervous system disorder that consists of the constant perception of small black and white dots throughout the entire visual field.</p></div><div><h3>Development</h3><p>VSS can present from infancy to old age, with greater prevalence in the young population, and shows no difference between sexes. The diagnostic criteria include the presence of visual snow and such other visual phenomena as palinopsia, photophobia, nyctalopia, and other persistent visual phenomena. The pathophysiology of VSS is unknown, but hyperexcitability of the visual cortex and a dysfunction in higher-order visual processing are postulated as potential mechanisms. The prevalence of migraine among patients with VSS is high, compared to the general population, and symptoms are more severe in patients presenting both conditions. No effective treatment is available, but the drug with the best results is lamotrigine, which is recommended only in selected cases with severe functional limitation.</p></div><div><h3>Conclusions</h3><p>VSS is a little-known and underdiagnosed entity, but the increasing number of studies in recent years has made it possible to establish diagnostic criteria and begin studying its pathophysiology. This entity is closely related to migraine, with overlapping symptoms and probably shared pathophysiological mechanisms.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 2","pages":"Pages 190-195"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580823000469/pdfft?md5=44bcdbff71126e2fa4919286cebc67d5&pid=1-s2.0-S2173580823000469-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9836647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Euthanasia and assisted suicide in neurological diseases: a systematic review","authors":"J.M. Trejo-Gabriel-Galán","doi":"10.1016/j.nrleng.2024.01.007","DOIUrl":"10.1016/j.nrleng.2024.01.007","url":null,"abstract":"<div><h3>Objective</h3><p>To identify the neurological diseases for which euthanasia and assisted suicide are most frequently requested in the countries where these medical procedures are legal and the specific characteristics of euthanasia in some of these diseases, and to show the evolution of euthanasia figures.</p></div><div><h3>Methods</h3><p>We conducted a systematic literature review.</p></div><div><h3>Results</h3><p>Dementia, motor neuron disease, multiple sclerosis, and Parkinson’s disease are the neurological diseases that most frequently motivate requests for euthanasia or assisted suicide. Requests related to dementia constitute the largest group, are growing, and raise additional ethical and legal issues due to these patients’ diminished decision-making capacity. In some countries, the ratios of euthanasia requests to all cases of multiple sclerosis, motor neuron disease, or Huntington disease are higher than for any other disease.</p></div><div><h3>Conclusions</h3><p>After cancer, neurological diseases are the most frequent reason for requesting euthanasia or assisted suicide.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 2","pages":"Pages 170-177"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000233/pdfft?md5=210bad3894f165e0b740016646cd39f2&pid=1-s2.0-S2173580824000233-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}